Cochrane · systematic review · CD002832
Perazine for schizophrenia
Leucht, S, Helfer, B, Hartung, B · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
9
No studies
4
Included studies
NR
No studies 4 · 28.6%Ungraded 1 · 7.1%Very low 3 · 21.4%Low 6 · 42.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Perazine versus placebo for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Acceptability of treatment Leaving the study early due to any reason Perazine vs placebo | RR 0.62 [0.35, 1.1] | 1 study · 95 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Global state change over time (no better or deterioration) Perazine vs placebo | RR 0.43 [0.23, 0.81] | 1 study · 95 participants | Low Downgraded: risk of bias, imprecision |
Overall mental state less than 30% BPRS reduction Perazine vs placebo | RR 0.82 [0.61, 1.09] | 1 study · 95 participants | Low Downgraded: risk of bias, imprecision |
Movement disorders number of participants receiving antiparkinson medication Perazine vs placebo | RR 4.5 [1.04, 19.45] | 1 study · 95 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Overall tolerability Leaving the studies early due to adverse events Perazine vs placebo | no estimate extracted | 0 studies · 0 participants | Ungraded |
Satisfaction with care ‐ not reported Perazine vs placebo | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Perazine vs placebo | no estimate extracted | NR | No studies |
Perazine versus other antipsychotics for schizophrenia
Population: patients with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state change over time (no better or deterioration) Perazine vs other antipsychotics | RR 1.33 [0.36, 4.97] | 1 study · 30 participants | Low Downgraded: risk of bias, imprecision |
Overall mental state BPRS endpoint score. Scale from: 0 to 108. Perazine vs other antipsychotics | no estimate extracted | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Movement disorders number of participants receiving antiparkinson medication Perazine vs other antipsychotics | RR 1.21 [0.53, 2.76] | 2 studies · 81 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Overall tolerability Leaving the study early due to adverse events Perazine vs other antipsychotics | RR 0.87 [0.4, 1.9] | 5 studies · 193 participants | Low Downgraded: risk of bias, imprecision |
Acceptability of treatment Leaving the studies early due to any reason Perazine vs other antipsychotics | RR 0.97 [0.68, 1.38] | 6 studies · 384 participants | Low Downgraded: risk of bias, imprecision, indirectness |
Satisfaction with care ‐ not reported Perazine vs other antipsychotics | no estimate extracted | NR | No studies |
Quality of life ‐ not reported Perazine vs other antipsychotics | no estimate extracted | NR | No studies |